In addition, our data are in keeping with those recently reported at the 2013 San Antonio Breast Cancer Symposium with the same regimen in 406 node-negative HER2-positive patients treated in the adjuvant setting [22]. This evidence concerns the gene ERBB2 and breast cancer.